专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2017113017A 抗ＣＤ１００抗体およびこれを使用するための方法审中-公开
公开(公告)号：JP2017113017A
公开(公告)日：2017-06-29
申请号：JP2017026605
申请日：2017-02-16
申请人：バクシネックスインコーポレーティッド , Vaccinex Inc , バクシネックスインコーポレーティッド
发明人： ERNEST S SMITH , TERRENCE LEE FISHER
IPC分类号： C12N15/09 , A61K35/76 , A61K38/00 , A61K38/43 , A61K39/395 , A61K45/00 , A61K47/34 , A61K47/42 , A61K47/44 , A61K47/50 , A61K49/00 , A61K51/00 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/02 , C12P21/08
CPC分类号： C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要：【課題】特定の自己免疫疾患、炎症疾患、及び癌を含む、CD100に関連する疾患を処置するための組成物及び方法の提供。【解決手段】CD100エピトープに特異的に結合する単離された抗体又はその抗原結合断片であって、CD100とCD100受容体との結合を阻害し、細胞傷害剤、治療剤、細胞増殖抑制剤、生物毒素、プロドラッグ、ペプチド、タンパク質、酵素、ウイルス、脂質、生物学的応答調節剤、薬剤、リンホカイン、異種抗体又はその断片、検出可能な標識、ポリエチレングリコール(PEG)、及び任意の該剤2つ以上の組み合わせからなる群より選択される剤と結合している、抗CD100モノクローナル抗体。【選択図】なし

2. 发明专利

TW200510455A 在乳癌和膀胱癌中差別表現之基因及其所編碼之多 GENE DIFFERENTIALLY EXPRESSED IN BREAST AND BLADDER CANCER AND ENCODED POLYPEPTIDES 审中-公开
简体标题：在乳癌和膀胱癌中差别表现之基因及其所编码之多 GENE DIFFERENTIALLY EXPRESSED IN BREAST AND BLADDER CANCER AND ENCODED POLYPEPTIDES
公开(公告)号：TW200510455A
公开(公告)日：2005-03-16
申请号：TW093111456
申请日：2004-04-23
申请人：法西尼克斯股份有限公司 VACCINEX, INC.
发明人：莫理斯羅德爾 ZAUDERER, MAURICE , 伊利莎白依凡斯 EVANS, ELIZABETH E. , 梅林達柏瑞羅 BORRELLO, MELINDA
IPC分类号： C07K , C07H
摘要：本發明涉及在人類癌症中差別表現的新穎人基因。更具體而言，本發明涉及編碼在人乳癌和膀胱癌中過度表現且稱為C35的新穎人多的多核酸。本發明亦涉及C35多(特別是C35抗原決定基和C35抗原決定基類似物)及載體、宿主細胞、C35多的抗體，及其重組製備方法。本發明進一步涉及檢測癌的診斷方法，該癌包括人乳癌。本發明另外涉及C35基因及多(特別是C35抗原決定基和C35抗原決定基類似物)在免疫原性組合物或疫苗中的調製和應用以誘導拮抗表現C35基因的靶細胞(例如腫瘤細胞)之抗體或細胞介導的免疫。本發明還涉及鑑定C35活性的激動劑和拮抗劑的篩選方法。
简体摘要：本发明涉及在人类癌症中差别表现的新颖人基因。更具体而言，本发明涉及编码在人乳癌和膀胱癌中过度表现且称为C35的新颖人多的多核酸。本发明亦涉及C35多(特别是C35抗原决定基和C35抗原决定基类似物)及载体、宿主细胞、C35多的抗体，及其重组制备方法。本发明进一步涉及检测癌的诊断方法，该癌包括人乳癌。本发明另外涉及C35基因及多(特别是C35抗原决定基和C35抗原决定基类似物)在免疫原性组合物或疫苗中的调制和应用以诱导拮抗表现C35基因的靶细胞(例如肿瘤细胞)之抗体或细胞介导的免疫。本发明还涉及鉴定C35活性的激动剂和拮抗剂的筛选方法。

3. 发明申请

WO2023048726A1 PREDICTIVE OUTCOME PROFILING FOR USE OF AN ANTI-SEMAPHORIN-4D BINDING MOLECULE TO TREAT NEURODEGENERATIVE DISORDERS 审中-公开
公开(公告)号：WO2023048726A1
公开(公告)日：2023-03-30
申请号：PCT/US2021/052142
申请日：2021-09-27
申请人： VACCINEX, INC.
发明人： ZAUDERER, Maurice , EVANS, Elizabeth , FISHER, Terrence
IPC分类号： C07K16/28 , A61P25/28 , A61K39/395 , A61B5/00
摘要： Provided herein are methods for selecting subjects having a neurodegenerative disorder for treatment with an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D), method for predicting the treatment outcome of subjects having a neurodegenerative disorder that are treated with an isolated binding molecule which specifically binds to SEMA4D and methods for treating subjects having a neurodegenerative disorder with an isolated binding molecule which specifically binds to SEMA4D.

4. 发明申请

WO2015061330A1 USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS 审中-公开
标题翻译：使用SEMAPHORIN-4D结合分子治疗神经损伤性疾病
公开(公告)号：WO2015061330A1
公开(公告)日：2015-04-30
申请号：PCT/US2014/061592
申请日：2014-10-21
申请人： VACCINEX, INC.
发明人： SMITH, Ernest S. , ZAUDERER, Maurice , BOWERS, William J. , JONASON, Alan
IPC分类号： A61K39/395 , A61K38/00
CPC分类号： C07K16/2896 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/30 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Provided are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors. Further provided is an isolated binding molecule which specifically binds to the same SEMA4D epitope as a reference monoclonal antibody selected from the group consisting of VX15/2503 and 67.
摘要翻译：本发明提供了减轻患有神经变性疾病的受试者症状的方法，其包括向受试者施用有效量的特异性结合信号素-4D（SEMA4D）或其Plexin-B1或Plexin-B2受体的分离的结合分子。还提供了分离的结合分子，其特异性结合相同的SEMA4D表位作为参考单克隆抗体，其选自VX15 / 2503和67。

5. 发明申请

WO2014121053A1 METHODS FOR INCREASING IMMUNOGLOBULIN A LEVELS 审中-公开
标题翻译：增加免疫球蛋白A水平的方法
公开(公告)号：WO2014121053A1
公开(公告)日：2014-08-07
申请号：PCT/US2014/014107
申请日：2014-01-31
申请人： VACCINEX, INC.
发明人： ZAUDERER, Maurice , YOSHIDA, Masaru , YAMAMOTO, Koji , SMITH, Ernest S.
IPC分类号： C07K16/24 , C07K16/28 , A61P29/00 , A61P31/00
CPC分类号： C07K16/24 , A61K2039/505 , A61K2039/545 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Methods for increasing immunoglobulin A (IgA) levels in a subject having a deficiency thereof are provided herein by administering to the subject an agent that inhibits CXCL13 activity, such as an anti-CXCL13 or an anti-CXCR5 antibody. Further provided are methods for treating an inflammatory disorder in a subject deficient for IgA by administering to the subject an agent that inhibits CXCL13 activity.
摘要翻译：本文通过向受试者施用抑制CXCL13活性的药物，例如抗CXCL13或抗CXCR5抗体，提供其具有缺乏症的受试者中增加免疫球蛋白A（IgA）水平的方法。还提供了通过向受试者施用抑制CXCL13活性的药物来治疗IgA缺陷的受试者的炎症性疾病的方法。

6. 发明申请

WO2012031099A3 ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME 审中-公开
标题翻译：抗CXCL13抗体及其使用方法
公开(公告)号：WO2012031099A3
公开(公告)日：2012-06-07
申请号：PCT/US2011050177
申请日：2011-09-01
申请人： VACCINEX INC , KLIMATCHEVA EKATERINA , PARIS MARK , SMITH ERNEST S
发明人： KLIMATCHEVA EKATERINA , PARIS MARK , SMITH ERNEST S
IPC分类号： C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/92
摘要： Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
摘要翻译：提供了用于治疗与CXCL13表达相关的疾病的组合物和方法，包括某些自身免疫性疾病，炎性疾病和癌症。具体而言，已开发抗CXCL13单克隆抗体来中和CXCL13。

7. 发明申请

WO2008100995A1 HUMANIZED ANTI-CD100 ANTIBODIES 审中-公开
标题翻译：人类抗CD100抗体
公开(公告)号：WO2008100995A1
公开(公告)日：2008-08-21
申请号：PCT/US2008/053816
申请日：2008-02-13
申请人： VACCINEX, INC. , SMITH, Ernest, S. , FISHER, Terrence, L., Jr. , ZAUDERER, Maurice
发明人： SMITH, Ernest, S. , FISHER, Terrence, L., Jr. , ZAUDERER, Maurice
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61P37/06
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods are provided for treating diseases associated with CDlOO, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD1OO antigen or a CD1OO antigen located on the surface of a human CD1OO- expressing cell, wherein the antibody has CD1OO blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.
摘要翻译：提供组合物和方法用于治疗与CD100相关的疾病，包括某些类型的癌症，自身免疫疾病，包括中枢神经系统（CNS）和周围神经系统（PNS）炎性疾病，移植排斥和侵袭性血管生成的炎性疾病。组合物包括能够结合位于人CD100表达细胞表面上的可溶性人CD100抗原或CD100抗原的抗CD100抗体，其中所述抗体具有通过具有至少一种优化的CDR或FWR获得的CD100阻断活性在抗体的可变区内工程化。组合物还包括单克隆抗体的抗原结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。本发明还包括药物组合物，其包含本发明的抗CD100抗体或其药学上可接受的载体中的抗原结合片段，变体或衍生物，以及使用这些抗CD100抗体的方法。

8. 发明申请

WO2008063771A2 ANTI-CD20 ANTIBODIES AND METHODS OF USE 审中-公开
标题翻译：抗CD20抗体和使用方法
公开(公告)号：WO2008063771A2
公开(公告)日：2008-05-29
申请号：PCT/US2007080925
申请日：2007-10-10
申请人： VACCINEX INC , SMITH ERNEST S , FISHER TERRENCE L JR
发明人： SMITH ERNEST S , FISHER TERRENCE L JR
IPC分类号： C07K16/00 , C12N5/0781
CPC分类号： C07K16/2887 , A61K39/39541 , A61K39/39558 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C12N5/0635 , C12N2501/599
摘要： Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.
摘要翻译：提供了用于治疗与CD20相关的疾病的组合物和方法，包括淋巴瘤，自身免疫疾病和移植排斥。组合物包括能够结合位于人CD20表达细胞表面上的人CD20抗原的抗CD20抗体，其中所述抗体具有增加的补体依赖性细胞介导的细胞毒性（CDC），其通过具有至少一个优化的 CDR在抗体的可变区内工程化。组合物还包括单克隆抗体的抗原结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体的氨基酸序列的分离的核酸分子。本发明进一步包括在药学上可接受的载体中包含本发明的抗CD20抗体或其抗原结合片段，变体或衍生物的药物组合物，以及这些抗CD20抗体的使用方法。

9. 发明申请

WO2007149586A3 ANTI-C35 ANTIBODIES FOR TREATING CANCER 审中-公开
公开(公告)号：WO2007149586A3
公开(公告)日：2007-12-27
申请号：PCT/US2007/014712
申请日：2007-06-22
申请人： VACCINEX, INC. , EVANS, Elizabeth, E. , PARIS, Mark, J. , SAHASRABUDHE, Deepak, M. , ZAUDERER, Maurice , SMITH, Ernest, S.
发明人： EVANS, Elizabeth, E. , PARIS, Mark, J. , SAHASRABUDHE, Deepak, M. , ZAUDERER, Maurice , SMITH, Ernest, S.
IPC分类号： A61K39/395
摘要： The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods.

10. 发明申请

WO2021226169A1 INTEGRAL MEMBRANE PROTEIN DISPLAY ON POXVIRUS EXTRACELLULAR ENVELOPED VIRIONS 审中-公开
公开(公告)号：WO2021226169A1
公开(公告)日：2021-11-11
申请号：PCT/US2021/030781
申请日：2021-05-05
申请人： VACCINEX, INC.
发明人： SMITH, Ernest S. , SCRIVENS, Maria G.M. , MUELLER, Loretta , SHI, Shuying , BALCH, Leslie A.
IPC分类号： C07K14/705 , C07K14/71 , C07K14/715 , C07K14/72 , C07K16/08 , C07K16/32 , C12N15/86
摘要： This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式